Making the Right Investment
Utility Game-Changers: Solar, Wind, Hydro and Fintech
Transformations in Financial Technologies
Innovation During a Global Crisis: Digital Banking Proves its Power
Increasing Competitive Advantage with Fintech
Selim Tastan, Head of Digital Transformation and Innovation, Kuveyt Turk Participation Bank
Fintech Solutions for the Exploding Savings Market - How banks can...
Paul Knodel, CEO and Managing Director, Raisin US Inc.
Go Big Data or Go Home-Data Analytics-Enabled Compliance Programs
Kevin Gleason, Senior Vice President at Voya Investment Management and Chief Compliance Officer of The Voya Funds & Matthew Gleason, Undergraduate Computer Science Major at The University of Arizona
Is it Time to Rethink Your Wellness Strategy?
Scott Mcduffie, Senior Director with Willis Towers Watson
Thank you for Subscribing to CIO Applications Weekly Brief
The company has raised a total capital of $300 million to date. Erasca intends to use the funds to finance the clinical development of multiple promising oncology programs, continue driving corporate development efforts, and further advance the company's in-house drug discovery pipeline.
FREMONT, CA: Erasca, a company whose mission is to erase cancer, completed the $36 million extension of its Series B financing round. This brings the total round to $236 million. New investors include OrbiMed and Partner Fund Management.
The company has raised a total capital of $300 million to date. Erasca intends to use the funds to finance the clinical development of multiple promising oncology programs, continue driving corporate development efforts, and further advance the company's in-house drug discovery pipeline.
"Erasca is honored to welcome Partner Fund Management and OrbiMed as partners in our bold mission of erasing cancer," stated Jonathan E. Lim, M.D., Erasca's chairman, CEO and co-founder. "We are doing everything we can to help patients live longer and healthier lives. Because cancer is such a formidable foe, we are grateful to have the support of our new and existing investors to tackle this terrible disease."
The company has assembled a resilient pipeline of precision therapies directed at undisclosed targets through in-house drug discovery and active pipeline expansion through collaborations with world-class academic and biopharmaceutical organizations.
"Erasca has demonstrated impressive progress in less than two years since its founding," added Mark Karvosky, a partner at Partner Fund Management. "The company's portfolio of potentially first-in-class and best-in-class assets will target significant unmet medical needs across multiple cancer types. We are excited to support this team and its programs, as Erasca strives to deliver practice-changing precision oncology therapies."
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Featured Vendors
-
Jason Vogel, Senior Director of Product Strategy & Development, Silver Wealth Technologies
James Brown, CEO, Smart Communications
Deepak Dube, Founder and CEO, Datanomers
Tory Hazard, CEO, Institutional Cash Distributors
Jean Jacques Borno, CFP®, Founder & CEO, 1787fp
-
Andrew Rudd, CEO, Advisor Software
Douglas Jones, Vice President Operations, NETSOL Technologies
Matt McCormick, CEO, AddOn Networks
Jeff Peters, President, and Co-Founder, Focalized Networks
Tom Jordan, VP, Financial Software Solutions, Digital Check Corp
Tracey Dunlap, Chief Experience Officer, Zenmonics